Let’s break down what’s at stake. Winkler and Witter, both California residents, served as directors at Navidea Biopharmaceuticals, Inc. Winkler was on the board for just two months, while Witter served less than three years. Both were named in a class action filed by shareholders in September 2024, with accusations ranging from facilitating the CEO’s removal to approving a string of complicated financial deals – think stock swaps, loan agreements, and changes to company bylaws. The lawsuit also points to Witter’s role in rejecting a multimillion-dollar tender offer.